DANCANN PHARMA A/S |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.056 DKK | -4.76% |
|
+86.67% | +86.67% |
| 03-29 | Dancann Pharma Plans Up to DKK19 Million Rights Issue | MT |
| 02-28 | DanCann Pharma Notes Cannabis Legalization in Germany as Shares Surge | MT |
| Sales 2021 | 874K 126K 10.03M | Sales 2022 | 7.19M 1.03M 82.49M | Capitalization | 37.06M 5.32M 425M |
|---|---|---|---|---|---|
| Net income 2021 | -11M -1.58M -126M | Net income 2022 | -16M -2.3M -184M | EV / Sales 2021 | 192 x |
| Net cash position 2021 | 7.74M 1.11M 88.76M | Net cash position 2022 | 10.75M 1.54M 123M | EV / Sales 2022 | 3.66 x |
| P/E ratio 2021 |
-12.7
x | P/E ratio 2022 |
-2.31
x | Employees | 10 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 14.49% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.76% | ||
| 1 week | +86.67% | ||
| Current month | -26.51% | ||
| 1 month | -26.51% | ||
| 3 months | +194.74% | ||
| 6 months | -30.00% | ||
| Current year | +86.67% |
1 week
0.03
0.08
1 month
0.020.08
Current year
0.010.10
1 year
0.010.58
3 years
0.017.06
5 years
0.017.06
10 years
0.017.06
| Managers | Title | Age | Since |
|---|---|---|---|
Jeppe Rasmussen
FOU | Founder | 29 | 19/03/18 |
| Director of Finance/CFO | 52 | 03/01/23 | |
| Chief Operating Officer | 37 | 31/03/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Carsten Trads
CHM | Chairman | 69 | - |
Tue Østergaard
BRD | Director/Board Member | 47 | 26/04/22 |
Jeppe Rasmussen
FOU | Founder | 29 | 19/03/18 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.056 | -4.76% | 2,343,351 |
| 25/04/24 | 0.0588 | -9.54% | 3,591,854 |
| 24/04/24 | 0.065 | +22.64% | 6,753,627 |
| 23/04/24 | 0.053 | +23.83% | 3,960,472 |
| 22/04/24 | 0.0428 | +42.67% | 5,440,444 |
End-of-day quote NORDIC GROWTH MARKET, April 25, 2024
More quotes
Dancann Pharma A/S is a Denmark-based pharmaceutical biotechnology company powered by cannabinoids. The Company is focused on discovering, developing, manufacturing, and commercializing of novel cannabinoid therapeutics in a broad range of disease areas. DanCann Pharma manufactures and distributes prescription drugs (Rx drugs) and over-the-counter drugs (OTCs), mainly focused on pain patients with alternative needs.
Calendar
28/05/2024
- Q1 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +86.67% | 1.34M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- DANCAN Stock
